IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

Heather A. Wakelee, Enriqueta Felip, Caicun Zhou et al.|Journal of Clinical Oncology|2024

Cited by 22